|
|
Volumn 31, Issue 3, 2014, Pages 245-246
|
|
A vision for drug discovery and development: Novel targets and multilateral partnerships
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIDEPRESSANT AGENT;
MILNACIPRAN;
MONOAMINE;
NEUROLEPTIC AGENT;
PSYCHOTROPIC AGENT;
TRICYCLIC ANTIDEPRESSANT AGENT;
VORTIOXETINE;
ACQUIRED IMMUNE DEFICIENCY SYNDROME;
ANXIETY DISORDER;
CONSENSUS;
DISEASE COURSE;
DRUG DEVELOPMENT;
DRUG EFFICACY;
DRUG MECHANISM;
DRUG REPOSITIONING;
DRUG TOLERABILITY;
EDITORIAL;
HEALTH CARE ORGANIZATION;
HUMAN;
INVESTMENT;
MENTAL DISEASE;
MONOAMINERGIC SYSTEM;
MOOD DISORDER;
MULTILATERAL PARTNERSHIP;
PSYCHOSIS;
PUBLIC HEALTH SERVICE;
PUNISHMENT;
QUALITY OF LIFE;
REIMBURSEMENT;
RETINA MACULA DEGENERATION;
TREATMENT OUTCOME;
UNITED STATES;
COOPERATION;
DEPRESSIVE DISORDER;
MENTAL DISORDERS;
PSYCHIATRY;
ANTIDEPRESSIVE AGENTS;
COOPERATIVE BEHAVIOR;
DEPRESSIVE DISORDER;
DRUG DISCOVERY;
HUMANS;
MENTAL DISORDERS;
PSYCHIATRY;
PSYCHOTROPIC DRUGS;
|
|
EID: 84898924742
PISSN: 0741238X
EISSN: 18658652
Source Type: Journal
DOI: 10.1007/s12325-014-0105-0 Document Type: Editorial |
|
Times cited : (23)
|
|
References (0)
|
